No Prescription |
 |
 | ||
|
STARSTAT EZ Vytorin |
|
| ||
No Prescription » Prescription Drugs 15 » STARSTAT EZ Vytorin Ezetimibe and simvastatin are cholesterol-lowering medicines. They reduce the amount of cholesterol (a type of fat) absorbed by the body and block the production of cholesterol in the body.The combination of ezetimibe and simvastatin lowers "bad" cholesterol in the blood (also called LDL or low-density lipoprotein) and raises "good" cholesterol (also called HDL or high-density lipoprotein). Lowering your LDL and raising your HDL cholesterol levels may reduce your risk of hardened arteries which can lead to heart attacks stroke and circulation problems. Buy STARSTAT EZ Vytorin and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About STARSTAT EZ Vytorin: Product Type: Prescription Drugs 15 STARSTAT EZ ( Vytorin Generic Ezetimibe/Simvastatin ) STARSTAT EZ (Vytorin Generic Ezetimibe/Simvastatin) Vytorin Generic Ezetimibe/Simvastatin 10/10mg Tabs Vytorin Generic Ezetimibe/Simvastatin STARSTAT EZ
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
